Rosetta Genomics LtdOver The Counter Market:ROSGQ
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0001
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Rosetta Genomics Ltd | 590.0 | 0.0x | --- |
International Stem Cell Corp | 569.9K | -4.3x | --- |
PhaseBio Pharmaceuticals Inc | 50.0 | 0.0x | --- |
Fresh Tracks Therapeutics Inc | 5.4M | -0.7x | --- |
Globeimmune Inc | 10.0 | 0.0x | --- |
Todos Medical Ltd | 2.1K | 0.0x | --- |
Company Information
Rosetta Genomics Ltd. is an Israel-based company engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA), and protein biomarkers, and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). The Company is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY, and RosettaGX Reveal. The Company's therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. The Company focuses on developing a diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification.
Contact Information
- Headquarters
- 10 Plaut Street, Science Park, Pob 4059REHOVOT, Israel 76706
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Brian Markison
- Chief Financial Officer
- Ron Kalfus
- Senior Director Of Finance
- Sigal Russo-Gueta
- Chief Scientific Officer
- Dganit Bar
- Vice President - Research
- Eti Meiri
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $590.00 |
|---|---|
Revenue (TTM) | $5.8M |
Shares Outstanding | 5.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -4.68 |
EPS | $-6.20 |
Book Value | $2.40 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -219.63% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
